OKYO Pharma (NASDAQ:OKYO) Trading Down 15.5% - What's Next?

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) shares fell 15.5% on Thursday . The stock traded as low as $2.31 and last traded at $2.39. 320,302 shares were traded during mid-day trading, an increase of 111% from the average session volume of 151,711 shares. The stock had previously closed at $2.83.Analyst Ratings ChangesA number of equities analysts have recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $7.00 price objective on shares of OKYO Pharma in a research report on Tuesday, September 23rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of OKYO Pharma in a report on Wednesday, October 8th. Finally, B. Riley began coverage on OKYO Pharma in a research note on Monday, December 8th. They issued a "buy" rating and a $5.00 price objective for the company. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $6.00.View Our Latest Report on OKYOOKYO Pharma Price PerformanceThe stock's fifty day moving average is $2.16 and its two-hundred day moving average is $2.37. Institutional Investors Weigh In On OKYO PharmaA hedge fund recently bought a new stake in OKYO Pharma stock. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 10,000 shares of the company's stock, valued at approximately $28,000. Institutional investors and hedge funds own 2.97% of the company's stock. About OKYO Pharma (Get Free Report)Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company's pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis. Okyo Pharma's lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.See AlsoFive stocks we like better than OKYO PharmaElon Taking SpaceX Public! $100 Pre-IPO Opportunity!How a Family Trust May Be Able To Help Preserve Your WealthA U.S. “birthright” claim worth trillions - activated quietlyExecutive Order 14330: Trump’s Biggest YetThe Crash Has Already Started (Most Just Don’t See It Yet)This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in OKYO Pharma Right Now?Before you consider OKYO Pharma, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.While OKYO Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here